Connie S Schmaljohn

US Patent:

6451309, Sep 17, 2002

Filed:

Feb 9, 2001

Appl. No.:

09/781124

Inventors:

Jay W. Hooper - New Market MD
Alan L. Schmaljohn - Frederick MD
Connie S. Schmaljohn - Frederick MD

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

A61K 3942

US Classification:

4241471, 4242321, 5303883

Abstract:

In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.

US Patent:

6562376, May 13, 2003

Filed:

Mar 7, 2001

Appl. No.:

09/800632

Inventors:

Jay W. Hooper - New Market MD
Alan L. Schmaljohn - Frederick MD
Connie S. Schmaljohn - Frederick MD

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

A61K 914

US Classification:

424489, 4241991, 514 44, 435459, 4353201, 4352351

Abstract:

In this application is described a poxvirus naked DNA vaccine which protects animals against poxvirus challenge comprising IMV and EEV nucleic acids from poxvirus. Methods of use of the vaccine and its advantages are described.

US Patent:

6620412, Sep 16, 2003

Filed:

Sep 16, 2002

Appl. No.:

10/202532

Inventors:

Jay W. Hooper - New Market MD
Alan L. Schmaljohn - Frederick MD
Connie S. Schmaljohn - Frederick MD

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

A61K 3942

US Classification:

4241471, 4242321, 5303883

Abstract:

In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.

US Patent:

7217812, May 15, 2007

Filed:

Mar 21, 2003

Appl. No.:

10/394388

Inventors:

Jay W. Hooper - New Market MD, US
Connie S. Schmaljohn - Frederick MD, US
Max Custer - Durham NC, US

Assignee:

United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

C07H 21/04

US Classification:

536 241, 536 2372, 4242041

Abstract:

In this application is described a protective DNA vaccines against infection with HFRS- and HPS-associated hantaviruses. The vaccines were constructed by subcloning cDNA representing the medium (M) (encoding the G1 and G2 glycoproteins) into the DNA expression vector pWRG7077. Animals vaccinated with the M construct developed a neutralizing antibody response. Passive transfer experiments show that serum from vaccinated animals, when injected on days 4 or 5 after challenge, protected animals from lethal disease.

US Patent:

7795015, Sep 14, 2010

Filed:

Mar 8, 2002

Appl. No.:

10/094546

Inventors:

Mary C. Guttieri - Myersville MD, US
Connie S. Schmaljohn - Frederick MD, US

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

C12N 15/63
C07K 16/00

US Classification:

4353201, 5303871

Abstract:

Three vectors are described which allow the conversion of Fab fragments into or single chain Fv fragments into full-length antibody molecules. Methods for using the vectors and the resulting antibodies are also described.

US Patent:

20020114818, Aug 22, 2002

Filed:

Jan 27, 2000

Appl. No.:

09/491974

Inventors:

Connie Schmaljohn - Frederick MD, US
J. Hooper - New Market MD, US

International Classification:

A61K048/00
C12N015/00

US Classification:

424/278100, 514/044000, 435/320100

Abstract:

Seoul virus (SEOV) is one of four known hantaviruses causing hemorrhagic fever with renal syndrome (HFRS). Candidate naked DNA vaccines for HFRS were constructed by subcloning cDNA representing the medium (M) (encoding the G1 and G2 glycoproteins) or small (S) (encoding the nucleocapsid protein) genome segment of SEOV into the DNA expression vector pWRG7077. We vaccinated BALB/c mice with three doses of the M or S DNA vaccine at 4-week intervals by either gene gun inoculation of the epidermis, or needle inoculation into the gastrocnemius muscle. Both routes of vaccination resulted in antibody responses as measured by ELISA; however, gene gun inoculation elicited a higher frequency of seroconversion, and higher levels of antibodies in individual mice. We vaccinated Syrian hamsters with the M or S construct using the gene gun and found hantavirus-specific antibodies in 5/5 and 4/5 hamsters, respectively. Animals vaccinated with the M construct developed a neutralizing antibody response which was greatly enhanced in the presence of guinea pig complement. Immunized hamsters were challenged with SEOV and, after 28 days, were monitored for evidence of infection. Hamsters vaccinated with M were protected from infection, but hamsters vaccinated with S were not protected.

US Patent:

20040082530, Apr 29, 2004

Filed:

Apr 11, 2003

Appl. No.:

10/411205

Inventors:

Connie Schmaljohn - Fort Detrick MD, US
James Fuller - Middleton WI, US

International Classification:

A61K048/00

US Classification:

514/044000

Abstract:

Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding an antigen from . Vectors and compositions containing these molecules are also described. Methods for eliciting an immune response using these molecules and compositions are also described.

US Patent:

20050148529, Jul 7, 2005

Filed:

Jan 5, 2004

Appl. No.:

10/751103

Inventors:

Connie Schmaljohn - Fort Detrick MD, US
James Fuller - Middleton WI, US

Assignee:

Powderject Vaccines, Inc. - Madison WI

International Classification:

A61K048/00
A61K039/07

US Classification:

514044000, 424246100

Abstract:

Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding an antigen from . Vectors and compositions containing these molecules are also described. Methods for eliciting an immune response using these molecules and compositions are also described.